We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$21.7B
AUM Growth
+$1.52B
(+7.6%)
Cap. Flow
-$396M
Cap. Flow
% of AUM
-1.83%
Top 10 Holdings %
Top 10 Hldgs %
30.74%
Holding
733
New
39
Increased
433
Reduced
235
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUY
Yamana Gold, Inc.
AUY
|
+$110M |
| 2 |
CRR
Carbo Ceramics Inc.
CRR
|
+$77.5M |
| 3 |
BTU
PEABODY ENERGY CORP COM STK NEW (DE)
BTU
|
+$77M |
| 4 |
PPP
Primero Mining Corp
PPP
|
+$75.2M |
| 5 |
Nabors Industries
NBR
|
+$74.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$84.2M |
| 2 |
SYT
Syngenta Ag
SYT
|
+$72.8M |
| 3 |
NOV
NOV
|
+$66.8M |
| 4 |
Deere & Co
DE
|
+$66.6M |
| 5 |
POT
Potash Corp Of Saskatchewan
POT
|
+$66.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 45.09% |
| 2 | Energy | 26.66% |
| 3 | Healthcare | 4.74% |
| 4 | Industrials | 3.46% |
| 5 | Consumer Staples | 2.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Texas Instruments
TXN
$255B
| $19.1M | 0.09% |
400,032
+38,879
| +11% | +$1.81M |
|
|
DRC
152
DELISTED
DRESSER-RAND GROUP INC
DRC
| $18.2M | 0.08% |
285,507
-28,633
| -9% | -$1.75M |
|
153
Sanofi
SNY
$104B
| $18.1M | 0.08% |
340,839
+30,248
| +10% | +$1.61M |
|
154
Applied Materials
AMAT
$426B
| $17.8M | 0.08% |
790,825
+27,286
| +4% | +$557K |
|
|
NVO
155
Novo Nordisk
NVO
$216B
| $17.5M | 0.08% |
758,188
+72,620
| +11% | +$1.6M |
|
|
ARMH
156
DELISTED
ARM HOLDINGS PLC ADS
ARMH
| $17.2M | 0.08% |
380,129
+43,781
| +13% | +$2.03M |
|
157
BioMarin Pharmaceuticals
BMRN
$11.5B
| $17.1M | 0.08% |
274,716
-73,010
| -21% | -$4.41M |
|
|
BRCM
158
DELISTED
BROADCOM CORP CL-A
BRCM
| $16.8M | 0.08% |
452,587
-34,071
| -7% | -$1.12M |
|
159
VEON
VEON
$3.53B
| $16.6M | 0.08% |
79,245
+4,588
| +6% | +$966K |
|
160
GSK
GSK
$103B
| $16.6M | 0.08% |
248,094
+18,557
| +8% | +$1.26M |
|
161
Eli Lilly
LLY
$1.07T
| $15.8M | 0.07% |
254,841
+15,019
| +6% | +$896K |
|
162
Analog Devices
ADI
$181B
| $15.8M | 0.07% |
292,762
+4,797
| +2% | +$254K |
|
163
AbbVie
ABBV
$458B
| $15.8M | 0.07% |
279,466
-26,013
| -9% | -$1.36M |
|
164
Telkom Indonesia
TLK
$14.2B
| $15.7M | 0.07% |
755,172
-183,620
| -20% | -$3.8M |
|
|
AGN
165
DELISTED
Allergan Inc
AGN
| $15.7M | 0.07% |
92,876
-17,481
| -16% | -$2.72M |
|
166
Bristol-Myers Squibb
BMY
$127B
| $15.7M | 0.07% |
322,731
+65,717
| +26% | +$3.24M |
|
167
AGNC Investment
AGNC
$12.3B
| $15.6M | 0.07% |
666,861
+88,582
| +15% | +$2.04M |
|
168
Abbott
ABT
$180B
| $15.5M | 0.07% |
378,885
+20,906
| +6% | +$821K |
|
169
Paramount Gold Nevada
PZG
$94.4M
| $15.3M | 0.07% |
15,923,890
+1,610,731
| +11% | +$1.67M |
|
170
Teva Pharmaceuticals
TEVA
$35.9B
| $15.3M | 0.07% |
291,563
+3,590
| +1% | +$183K |
|
171
AstraZeneca
AZN
$263B
| $15.2M | 0.07% |
204,196
-8,755
| -4% | -$633K |
|
172
Jacobs Solutions
J
$15.9B
| $14.7M | 0.07% |
334,387
-645,967
| -66% | -$30.7M |
|
|
MDVN
173
DELISTED
MEDIVATION, INC.
MDVN
| $14.7M | 0.07% |
382,316
-61,124
| -14% | -$2.06M |
|
174
Tidewater
TDW
$3.91B
| $14.4M | 0.07% |
7,939
+120
| +2% | +$199K |
|
|
PCYC
175
DELISTED
PHARMACYCLICS INC
PCYC
| $14.4M | 0.07% |
160,267
+6,502
| +4% | +$610K |
|
Similar funds
DAM
VanEck Associates's Q2 2014 Portfolio in Review
As of Q2 2014, VanEck Associates held 733 positions worth $21.7B, up 7.6% from $20.1B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
VanEck Associates's Q2 2014 filing shows 39 new, 433 increased, 235 reduced and 15 closed positions. Its largest new stake was MAG Silver: 5,536,686 shares worth $52.4M. The largest sale was Monsanto Co, an estimated $84.2M.
By sector, the portfolio is most concentrated in Materials at 45% of assets, up from 45% a quarter earlier, followed by Energy and Healthcare.
- VanEck Associates's largest Q2 2014 buy was MAG Silver: 5,536,686 shares worth $52.4M.
- VanEck Associates added most to Yamana Gold, Inc. in Q2 2014, an estimated $110M increase.
- VanEck Associates's biggest Q2 2014 reduction was Monsanto Co, cutting an estimated $84.2M.
- VanEck Associates fully exited Weatherford International plc in Q2 2014, selling an estimated $45.6M.
- VanEck Associates's ten largest holdings make up 31% of its $21.7B portfolio in Q2 2014.
- VanEck Associates opened 39 new positions and closed 15 in Q2 2014.
- VanEck Associates's portfolio value rose 7.6% quarter-over-quarter to $21.7B.
Based on VanEck Associates's 13F filing for Q2 2014, filed 14 Aug 2014.